The company's founder and CEO announced the availability of the Rad-97 Pulse-CO Oximeter and Next Generation SedLine Brain Function Monitoring at a roundtable of the CEOs of top Bangalore hospitals.

The Rad-97 device includes measure-through motion and low perfusion SET pulse oximetry, which enables clinicians to reduce severe retinopathy of prematurity in neonates and improve CCHD screening in newborns.

It features the same upgradeable rainbow SET technology as the Radical-7 Pulse CO-Oximeter, helping clinicians to monitor rainbow measurements as total hemoglobin (SpHb) and PVi.

The Rad-97 device also includes a camera for clinician tele-presence through Patient SafetyNet and high-resolution 1080p HD color display with user-friendly multi-touch navigation.

In addition, the rainbow will measure methemoglobin (SpMet), acoustic respiration rate (RRa), carboxyhemoglobin (SpCO), oxygen reserve index (ORi), and oxygen content (SpOC).

SedLine includes four simultaneous EEG leads, which will help in continuous assessment of both sides of the brain.

It will also feature density spectral array (DSA), an easy-to-interpret and high-resolution display of bi-hemispheric activity.

SedLine is said to enhance Masimo’s processed EEG parameter, the patient state index (PSI), making it less susceptible to electromyographic (EMG) interference and improve performance in low-power EEG cases.

Masimo founder and CEO Joe Kiani said: “The Indian healthcare sector recognizes the need for technologies that help their clinicians get the best results, the first time.

“Masimo’s noninvasive patient monitoring technology innovations offer capabilities that have never been possible before.”

Masimo India country manager Bharat Monteiro said: “Masimo is committed to doing what is best for patient care in India. In the course of our engagement with leading Indian hospitals, we have witnessed an increased awareness of and commitment to patient safety requirements.”

Image: Masimo Rad-97 Pulse CO-Oximeter. Photo: courtesy of Masimo.